B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma

American Journal of Clinical Pathology

Volumn 137, Issue 5, 2012, Pages 805-814

  Bashashati, Ali ^a   Johnson, Nathalie A ^c   Khodabakhshi, Alireza Hadj ^a   Whiteside, Matthew D ^d   Zare, Habil ^b   Scott, David W ^a   Lo, Kenneth ^e   Gottardo, Raphael ^f   Brinkman, Fiona S L ^d   Connors, Joseph M ^a   Slack, Graham W ^a   Gascoyne, Randy D ^a   Weng, Andrew P ^a,b   Brinkman, Ryan R ^b,g  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diffuse large B cell lymphoma; Flow cytometry; Lymphoma; Side scatter; Survival

Indexed keywords

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARAMETERS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE SCATTER; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84862598238     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPGR8BG4JDVOWR     Document Type: Article

References (45)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Harris NL, Jaffe ES, Stein H, et al. Perspective: a revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392. (Pubitemid 24273002)
3. Stein H, Dallenbach F. Diffuse large cell lymphomas of B and T cell type. Neoplastic Hematopathology. Baltimore, MD: Williams & Wilkins; 1992:675-714.
4. Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev. 1998;162:261-280. (Pubitemid 28182141)
5. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol. 1996;14:2131-2138. (Pubitemid 26230116)
6. Dalla-Favera R, Ye BH, Cattoretti G, et al. BCL-6 in diffuse large-cell lymphomas. Important Adv Oncol. 1996:139-148.
7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
8. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of BCL-2 protein expression and BCL-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251. (Pubitemid 27276568)
9. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001;98:945-951.
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511. (Pubitemid 30082188)
11. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279-4284. (Pubitemid 36857789)
12. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of BCL-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207-4213. (Pubitemid 43801342)
13. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282. (Pubitemid 38029949)
14. De Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol. 2009;62:128-138.
15. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009;113:3773-3780.
16. Wu G, Keating A. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer. 2006;106:247-257. (Pubitemid 43100431)
17. Bagwell CB. DNA histogram analysis for node-negative breast cancer. Cytometry A. 2004;58:76-78. (Pubitemid 38337834)
18. Maecker H, Maino V. Flow cytometric analysis of cytokines. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical Laboratory Immunology. 6th ed. Washington, DC: ASM Press; 2002:338-346.
19. Roederer M, Hardy RR. Frequency difference gating: a multivariate method for identifying subsets that differ between samples. Cytometry. 2001;45:56-64. (Pubitemid 32807924)
20. Suni MA, Dunn HS, Orr PL, et al. Performance of plate-based cytokine flow cytometry with automated data analysis. BMC Immunol. 2003;4:9. doi:10.1186/1471-2172-4-9.
21. Ramsay JO, Silverman BW. Functional Data Analysis. Berlin, Germany: Springer; 1996.
22. Herzenberg LA, Parks D, Sahaf B, et al. The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem. 2002;48:1819-1827.
23. Overton WR. Modified histogram subtraction technique for analysis of flow cytometry data. Cytometry. 1988;9:619-626. (Pubitemid 18264743)
24. Roederer M. Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry. 2001;45:194-205. (Pubitemid 33064141)
25. Krutzik PO, Irish JM, Nolan GP, et al. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol. 2004;110:206-221. (Pubitemid 38402001)
26. De Rosa SC, Brenchley JM, Roederer M. Beyond six colors: a new era in flow cytometry. Nat Med. 2003;9:112-117. (Pubitemid 36098271)
27. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nature Reviews Immunology. 2004;4:648-655. (Pubitemid 39025050)
28. Bashashati A, Brinkman R. A survey of flow cytometry data analysis methods. Adv Bioinformatics. 2009:584603. doi:10.1155/2009/584603.
29. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431-2442. (Pubitemid 43855046)
30. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996. (Pubitemid 37087056)
31. Lo K, Brinkman RR, Gottardo R. Automated gating of flow cytometry data via robust model-based clustering. Cytometry A. 2008;73:321-332. (Pubitemid 351522115)
32. Hastie T, Tibshirani R, Friedman J, et al. The elements of statistical learning: data mining, inference and prediction. Mathematical Intelligencer. 2005;27:83-85.
33. Hahne F, Meur NL, Brinkman R, et al. flowCore: a Bioconductor package for high throughput flow cytometry. BMC Bioinformatics. 2009;10:106. doi:10.1186/1471-2105-10-106.
34. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15. doi:10.1093/nar/ gng015.
35. Bolstad B, Irizarry R, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185-193. (Pubitemid 36181903)
36. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80. doi:10.1186/gb-2004-5-10-r80.
37. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:article 3. doi:10.2202/1544-6115.1027.
38. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100:9440-9445. (Pubitemid 37033947)
39. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25:25-29. (Pubitemid 30257031)
40. Goeman JJ, van De Geer SA, De Kort F, et al. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics. 2004;20:93-99. (Pubitemid 38088346)
41. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
42. Cox D. Regression models and life-tables. J R Stat Soc Series B (Methodol). 1972;34:187-220.
43. Goval JJ, Thielen C, Bourguignon C, et al. The prevention of spontaneous apoptosis of follicular lymphoma B cells by a follicular dendritic cell line: involvement of caspase-3, caspase-8 and c-FLIP. Haematologica. 2008;93:1169-1177.
44. Del Gaizo Moore V, Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? In: Khosravi-Far R, White E, eds. Programmed Cell Death in Cancer Progression and Therapy. 2007:159-175. Advances in Experimental Medicine and Biology; Vol 615.
45. Lenz G, Wright G, Dave S, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.